ROKIT
Organ Regeneration Platform

AI bioprinting innovation
regenerates life

AI Hyper-personalized Organ Regeneration Platform

A New Hope for Chronic Disease

we are pioneering a transformative approach to treating diabetic foot complications with our cutting-edge organ regeneration platform. Diabetic foot ulcers, chronic kidney disease, and degenerative arthritis are serious conditions affecting millions, often leading to severe complications and reduced quality of life. Our innovative platform, powered by advanced AI and 3D bioprinting technology, offers new hope for patients suffering from these debilitating conditions.

The Challenge of Chronic Diseases

Chronic diseases require long-term treatment and management, placing a significant physical, emotional, and economic burden on patients. Diabetic foot ulcers are open sores on the bottom of the foot, posing a high risk of infection and amputation. Chronic kidney disease involves the gradual loss of kidney function, often necessitating dialysis or transplantation. Degenerative arthritis leads to cartilage wear, causing pain and movement limitations. Traditional treatments often have limitations, highlighting the urgent need for more effective solutions to treat these diseases.

Life Transformation

ROKIT Healthcare’s organ regeneration platform effectively treats chronic diseases such as diabetic foot ulcers, chronic kidney disease, and degenerative arthritis. By promoting rapid healing and tissue regeneration, we offer new hope and improved quality of life for patients.

Our mission is to enhance the lives of chronic disease patients. Through innovative regenerative technology, we aim to transform the lives of millions worldwide by providing faster healing and reducing the risk of complications.

01

Precision Bioprinting

Using state-of-the-art 3D bioprinters, we create custom tissue grafts tailored to each patient’s specific needs. These grafts are designed to seamlessly integrate with the patient’s own tissues, promoting natural healing and regeneration.

02

AI-Driven Customization

Our advanced AI algorithms analyze patient data to optimize the design and composition of the bioprinted tissues. This ensures that each graft is perfectly suited to the individual’s condition, maximizing the effectiveness of the treatment.

03

Rapid Regeneration

The bioprinted grafts facilitate the regeneration of skin and other tissues, significantly accelerating the healing process. This not only reduces the risk of infection but also enhances the overall recovery experience for patients

Welcome to Organ Regeneration Platform

Dear Visitors,

Welcome to the ROKIT Healthcare Organ Regeneration Platform. As the CEO, I am proud to share our mission of revolutionizing healthcare through cutting-edge technologies.

Our AI Hyper-personalized Organ Regeneration Platofrm has earned significant recognition, securing approvals from the FDA, CE-MDR, and Korea’s Ministry of Health and Welfare as an innovative medical technology. Additionally, we are honored to have received the Excellent Company Award from the Ministry of Science and ICT, which acknowledges our commitment to innovation and technical excellence.

Currently, our groundbreaking products are available in 18 countries worldwide, underscoring our global impact and recognition. Our platform aims to address critical healthcare challenges by offering regenerative solutions for conditions like diabetic foot ulcers, chronic kidney disease, and degenerative arthritis. We are dedicated to providing new hope and improved quality of life for patients around the globe.

Thank you for visiting our website and joining us on this journey towards a brighter, healthier future. Your support and collaboration are invaluable as we continue to lead the way in medical innovation.

Warm regards,

You SeokHwan
Founder and CEO

Global recognition and awards related to technology

Obtained 2023 CE MDR (Medical Device Regulation) Certification
Notification of Innovative Medical Technology (Minister of Health and Welfare) – ‘3D Printing-Based Diabetic Foot Treatment Technology
Winner of the Innovation Technology Showcase Award at the 2023 GSMA M360 APAC 2023 DX Acceleration Summit
Designated as a Global IP (Intellectual Property) Star Company by the Seoul Business Agency
Selected as an IDC Innovators 2022 Asia-Pacific Region Video AI Solution Company
2021 Intellectual Property Management Certification by the Commissioner of the Korean Intellectual Property Office
2021 Preliminary Unicorn Company – by the Ministry of SMEs and Startups and the Korea Technology Finance Corporation
Presentation of Skin Regeneration Clinical Results at the Diabetic Foot Conference (DFCon) held in the United States in 2021, Winning 3rd Place
Winner of the Technology Innovation Management Category at the 2021 Chosun Ilbo Business Awards
Presented at the American Association of Pharmaceutical Scientists (AAPS), a Global Arena for Pharmaceutical Science and Technology, in 2019, Winning 1st Place
Top 50 Healthcare Companies’ at the 2019 IFAH International Healthcare Forum
Winner of the Top 10 Technology Awards by the Federation of Korean Mechanical Engineering Associations in 2018 (Jointly Awarded with the Korea Institute of Machinery & Materials)
Selected as This Year’s Outstanding Biotech Company at the Bioindustry Performance Sharing and IT Exchange Meeting hosted by the Korea Bio Association/Korea Industrial Technology Evaluation and Management Institute, Awarded by the Minister of Trade, Industry and Energy.
Stay Connected with Us

Let’s Create Together

Connect with us to explore how we can make your vision a reality. Join us in shaping the future.

Join Now

R&BD Global Academy & Certification Performance

We have achieved global commercialization through active R&BD activities such as clinical research, global contracts, and participation in international conferences for skin and diabetic foot regeneration platforms.

Participation and Oral Presentation on Organ Regeneration Platform at the NABICON (National Burn Conference of India) in March 2019
IEC Approval for Diabetic Foot Treatment Clinical Trials in India in August 2019 (Overseen by Dr. Rajesh Kesavan, Member of the Indian Diabetic Foot Society)
Exhibition and Presentation at the American Association of Pharmaceutical Scientists (AAPS) Conference in January 2019, Winning the ‘Tech Challenge Winner’ Presentation Award
Selection and Publication of Diabetic Foot Clinical Results Abstract by the American Diabetes Association (ADA) in June 2020
IRB Approval for Domestic Diabetic Foot Treatment Clinical Trials in April 2020 (Professor Han Seung-kyu, President of the Korean Diabetic Foot Society and Director of Korea University Guro Hospital)
Secured Investment from DRADS Capital Investment in July 2020 (Fund by Professor Tanzi, a Neuroscientist Authority at Harvard University)
Dr. Invivo, Medical Device Kit Registered with the U.S. FDA in August 2020
Exclusive Distribution Agreement for Skin Regeneration Platform in Malaysia/Singapore/Brunei with DUOPHARMA BIOTECH in November 2020″
Exclusive Distribution Agreement for Skin Regeneration Platform with ELIXYM in Colombia and Two Other South American Countries in November 2020
Exclusive Distribution Agreement for Skin Regeneration Platform with Cigalah Group in Saudi Arabia, UAE, and Seven Other Middle Eastern Countries in November 2020
Oral Presentation of Diabetic Foot Clinical Results at the 5th Middle East International Dermatology & Aesthetic Medicine Conference (MEIDAM) in December 2020
IRB Approval for Diabetic Foot Treatment Clinical Trials in the United States in December 2020 (Overseen by Dr. David Armstrong, Founder of the American Diabetic Foot Society and USC Professor)
United Arab Emirates Ministry of Health and Prevention Medical Device Approval for Dr. Invivo and Medical Device Kits in December 2020
IRB Approval for Diabetic Foot Treatment Clinical Trials in Turkey in January 2021 (Overseen by Dr. Cinar Yasti, Director of the Burn Center at the National Ankara Hospital in Turkey)
First Export of Skin Regeneration Platform to the Middle East (UAE) in March 2021
Preclinical Results Presentation of Renal Failure Patch at the World Congress of Nephrology (WCN) in April 2021
Exclusive Distribution Agreement with Intra Medikal in Turkey in May 2021
Invited Oral Presentation and Exhibition of Skin Regeneration Platform at the Emirates Plastic Surgery Congress in the UAE in May 2021
IRB Approval for Diabetic Foot Treatment Clinical Trials in Malaysia in May 2021 (Overseen by Dr. Yazid, Professor at the National University Hospital of Malaysia)
Regional Sales Agreement Signed with Corin Healthcare in South Korea in June 2021
Notification from the Ministry of Food and Drug Safety in August 2021 that the Skin/Cartilage/Kidney Regeneration Platform is Not Subject to the Advanced Regenerative Medicine Act
Launch of Decellularization Equipment at the Korean Society for Stem Cell Research (KSSCR) in August 2021
Invited Presentation at the Korean Society of Nephrology (KSN) in September 2021
Invited Poster/Oral Presentation of Skin Regeneration Platform at the Diabetic Foot Conference (DFCon) in the United States in January 2021, Winning 3rd Place in Presentation Award
Exclusive Distribution Agreement for Skin Regeneration Platform in India with Alkem Laboratories in January 2021
Invited Oral Presentation of Tissue Regeneration Platform at the Tissue Engineering and Regenerative Medicine International Society (TERMIA) Conference in November 2021 (Online)
Invited Oral Presentation and Exhibition of Skin Regeneration Platform at the Malaysia Wound Association ‘Wound War’ in November 2021
Invited Oral Presentation and Exhibition of Skin Regeneration Platform at the Indian Diabetic Foot Society (DFSICON) in December 2021
Exclusive Distribution Agreement for Skin Regeneration Platform in Brazil with 1000Medic in January 2022
Exclusive Distribution Agreement for Skin Regeneration Platform in Thailand/Philippines with SRS Life Science in January 2022
FDA Kit Registration in the United States in February 2022
IRB Approval for Reconstruction Clinical Trials after Skin Cancer Excision (Supervised by Professor Han Seung-kyu at Korea University Guro Hospital) in April 2022
Registration with the Indian Food and Drug Administration in April 2022
First Export of Skin Regeneration Platform to South Asia (India) in May 2022
Presentation and Exhibition at the American Academy of Orthopaedic Surgeons (AAOS 2022) Conference in May 2022
Medical Device Registration with the Brazilian Health Regulatory Agency in June 2022
First Export of Skin Regeneration Platform to South America (Brazil) in June 2022
Exclusive Distribution Agreement for Skin Regeneration Platform in Paraguay with Bioethics Pharma in June 2022
Invited Oral Presentation of Skin Regeneration Platform at the Congress of Angiology and Vascular Surgery in Brazil in June 2022
Invited Oral Presentation of Tissue Regeneration Platform at the TERMIS-America Conference in July 2022
Invited Oral Presentation of Skin Regeneration Platform at the Brazilian Wound Healing Society (SIITTRAL) in August 2022
Exhibition at the Japanese Society of Pressure Ulcers in August 2022
Medical Device Approval for Kit by the Paraguayan Regulatory Authority in September 2022
Exclusive Distribution Agreement for Skin Regeneration Platform with Laboratorio Varifarma S.A. (Argentina) in October 2022
Participation and Oral Presentation with Exhibition of Skin Regeneration Platform at the Symposium on Advanced Wound Care (SAWC) in October 2022
Medical Device Kit Registration with Domestic Regulatory Authority in December 2022
Participation and Oral Presentation with Skin Regeneration Platform at the Japanese Society for Wound Healing Conference in November 2022
Completion of Medical Device Kit Approval by the Saudi Food and Drug Authority in November 2022
Exclusive Distribution Agreement for Skin Regeneration Platform with Laboratorio LIBRA S.A. in Uruguay in December 2022
Exclusive Distribution Agreement for Cartilage Regeneration Platform with Gabblan Pharmaceutical in Peru in January 2023
Exclusive Distribution Agreement for Skin Regeneration Platform with SRS Life Science in Russia in February 2023
Participation and Oral Presentation with Skin Regeneration Platform at the Japanese Foot and Ankle Society Conference in February 2023
Exclusive Distribution Agreement for Skin Regeneration Platform with Varifarma Chile in March 2023
Presentation on the Efficacy and Safety of Skin Graft Patch at the World Congress of Nephrology (WCN) in March 2023
Presentation and Clinical Demonstration at the Argentina Vascular Conference in April 2023
Exclusive Distribution Agreement for Skin Regeneration Platform with Infinity Advanced Technology Solutions in Ethiopia in May 2023
Exclusive Distribution Agreement for Skin Regeneration Platform with Tides Medical in the United States in April 2023
Exclusive Distribution Agreement for Skin Regeneration Platform with Emerge Lab in Mexico in May 2023
Exhibition/Seminar Presentation and Clinical Demonstration at the Vascular Conference in Chile in June 2023
Approval Completion for Medical Device Kits by the Thai FDA in June 2023
Exhibition and Presentation at the Korean Medical 3D Printing Society in June 2023
First Export of Skin Regeneration Platforms to the United States in July 2023
IRB Approval for Clinical Trials of Diabetic Foot Treatment in Japan in August 2023
IRB Approval for Clinical Trials of Diabetic Foot Treatment in Ethiopia in August 2023

Get in touch

Join Now

Pages

Family Websites

Follow us

Scroll to Top